Table 4.
The histopathologic features of the tumors.
| Histopathologic features | Group 1 | Group 2 | Group 3 | p | |
|---|---|---|---|---|---|
| n (%) | n (%) | n % | |||
| No. of tumor | |||||
| Single | n (%) | 776 (89.7) | 48 (82.8) | 137 (81.5) | 0.019 |
| Multiple | 85 (9.8) | 9 (15.5) | 30 (17.9) | ||
| Inflammatory | 4 (0.5) | 1 (1.7) | 1 (0.6) | ||
| Carcinoma In situ | |||||
| Yes | n (%) | 346 (46.6) | 23 (44.2) | 42 (38.5) | 0.285 |
| No | 397 (53.4) | 29 (55.8) | 67 (61.5) | ||
| Histology | |||||
| IDC | n (%) | 722 (77.8) | 43 (63.2) | 151 (81.6) | < 0.001 |
| ILC | 73 (7.9) | 10 (14.7) | 13 (7.0) | ||
| Mixed | 50 (5.4) | 12 (17.6) | 10 (5.4) | ||
| Other | 83 (8.9) | 3 (4.4) | 11 (5.9) | ||
| Histologic grade | |||||
| 1 | n (%) | 78 (10.6) | 2 (4.1) | 2 (1.6) | 0.004 |
| 2 | 451 (61.0) | 31 (63.3) | 76 (59.4) | ||
| 3 | 210 (28.4) | 16 (32.7) | 50 (39.1) | ||
| Nuclear grade | |||||
| 1 | n (%) | 37 (6.0) | 2 (5.3) | 2 (2.2) | 0.274 |
| 2 | 420 (67.7) | 23 (60.5) | 56 (62.9) | ||
| 3 | 163 (26.3) | 13 (34.2) | 31 (34.8) | ||
| Mitosis | |||||
| 1 | n (%) | 153 (25.5) | 14 (37.8) | 15 (17.0) | 0.006 |
| 2 | 370 (61.8) | 17 (45.9) | 51 (58.0) | ||
| 3 | 76 (12.7) | 6 (16.2) | 22 (25.0) | ||
| ER | |||||
| Neg | n (%) | 243 (27.0) | 20 (30.3) | 74 (41.3) | 0.002 |
| 1+ | 135 (15.0) | 8 (12.1) | 28 (15.6) | ||
| 2++ | 168 (18.7) | 16 (24.2) | 32 (17.9) | ||
| 3+++ | 354 (39.3) | 22 (33.3) | 45 (25.1) | ||
| Percentage of ER | Median (Min–Max) | 80 (1–100) | 70 (5–100) | 70 (2–100) | 0.139 |
| PR | |||||
| Neg | n (%) | 271 (30.3) | 23 (34.3) | 65 (37.1) | 0.03 |
| 1+ | 158 (17.7) | 15 (22.4) | 43 (24.6) | ||
| 2++ | 153 (17.1) | 13 (19.4) | 30 (17.1) | ||
| 3+++ | 312 (34.9) | 16 (23.9) | 37 (21.1) | ||
| Percentage of PR | Median (Min–Max) | 60 (0–100) | 50 (0–100) | 50 (1–100) | 0.003 |
| cerbB2 | |||||
| Negative | n (%) | 569 (77.4) | 40 (75.5) | 94 (67.6) | 0.047 |
| Positive | 166 (22.6) | 13 (24.5) | 45 (32.4) | ||
| P53 | |||||
| Negative | n (%) | 312 (40.1) | 27 (44.3) | 74 (50.7) | 0.053 |
| Positive | 467 (59.9) | 34 (55.7) | 72 (49.3) | ||
| Ki67 | |||||
| ≤ 14% | n (%) | 439 (58.1) | 26 (49.1) | 61 (44.9) | 0.01 |
| > 14% | 316 (41.9) | 27 (50.9) | 75 (55.1) | ||
| Percentage of Ki67 | Median (Min–Max) | 15 (1–90) | 15 (1–80) | 25 (1–90) | < 0.001 |
| E-cadherin | |||||
| Negative | n (%) | 38 (9.9) | 3 (13.0) | 5 (8.5) | 0.823 |
| Positive | 344 (90.1) | 20 (87.0) | 54 (91.5) | ||
| Lymph vessel invasion | |||||
| No | n (%) | 515 (76.9) | 19 (42.2) | 47 (48.0) | < 0.001 |
| Yes | 155 (23.1) | 26 (57.8) | 51 (52.0) | ||
| Blood vessel invasion | |||||
| No | n (%) | 558 (83.3) | 32 (69.6) | 62 (67.4) | < 0.001 |
| Yes | 112 (16.7) | 14 (30.4) | 30 (32.6) | ||
| Molecular classification | |||||
| Luminal A | n (%) | 319 (37.2) | 20 (31.3) | 36 (21.4) | 0.003 |
| Luminal B | 364 (42.4) | 30 (46.9) | 79 (47.0) | ||
| Triple negative | 112 (13.1) | 10 (15.6) | 33 (19.6) | ||
| HER2 enriched | 63 (7.3) | 4 (6.3) | 20 (11.9) | ||
IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PR progestrone receptor.